Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

• Published in: Journal of clinical oncology Vol. 25; no. 30; pp. 4722 - 4729
• Main Authors: VREDENBURGH, James J, DESJARDINS, Annick, WAGNER, Melissa, BAILEY, Leighann, BIGNER, Darell D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, HERNDON, James E, MARCELLO, Jennifer, REARDON, David A, QUINN, Jennifer A, RICH, Jeremy N, SATHORNSUMETEE, Sith, GURURANGAN, Sridharan, SAMPSON, John
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20-10-2007; Lippincott Williams & Wilkins
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Female; Glioblastoma - drug therapy; Glioblastoma - pathology; Humans; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Staging; Neurology; Prognosis; Survival Rate; Tumors; Tumors of the nervous system. Phacomatoses; Antineoplastic agent; Nervous system diseases; Relapse; Enzyme; DNA topoisomerase; Enzyme inhibitor; Monoclonal antibody; Malignant tumor; Glioblastoma multiforme; Bevacizumab; Malignant glioma; Irinotecan; Isomerases; Cancerology; Vascular endothelium growth factor; Central nervous system disease; Antagonist
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2007.12.2440

The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan.
This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme-inducing antiepileptic drugs (EIAEDs) received 340 mg/m2, and patients not taking EIAEDs received 125 mg/m2. After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab. The second cohort, comprising 12 patients, received bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Each cycle was 6 weeks long and concluded with patient evaluations, including magnetic resonance imaging.
The 6-month progression-free survival among all 35 patients was 46% (95% CI, 32% to 66%). The 6-month overall survival was 77% (95% CI, 64% to 92%). Twenty of the 35 patients (57%; 95% CI, 39% to 74%) had at least a partial response. One patient developed a CNS hemorrhage, which occurred in his 10th cycle. Four patients developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli).
Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.